Seizert Capital Partners LLC Purchases 1,403 Shares of Amgen Inc. (NASDAQ:AMGN)

Seizert Capital Partners LLC grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 192,842 shares of the medical research company’s stock after acquiring an additional 1,403 shares during the quarter. Amgen accounts for 2.8% of Seizert Capital Partners LLC’s holdings, making the stock its 4th biggest position. Seizert Capital Partners LLC’s holdings in Amgen were worth $62,136,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. M&G Plc bought a new position in Amgen in the first quarter valued at approximately $7,633,000. Patten & Patten Inc. TN raised its position in Amgen by 4.6% during the first quarter. Patten & Patten Inc. TN now owns 3,104 shares of the medical research company’s stock worth $883,000 after acquiring an additional 136 shares in the last quarter. Edgestream Partners L.P. lifted its stake in Amgen by 218.0% in the first quarter. Edgestream Partners L.P. now owns 12,434 shares of the medical research company’s stock valued at $3,535,000 after acquiring an additional 8,524 shares during the last quarter. Hillsdale Investment Management Inc. grew its position in shares of Amgen by 44.3% in the 1st quarter. Hillsdale Investment Management Inc. now owns 1,400 shares of the medical research company’s stock valued at $398,000 after acquiring an additional 430 shares during the period. Finally, Trustmark National Bank Trust Department increased its stake in shares of Amgen by 6.5% during the 1st quarter. Trustmark National Bank Trust Department now owns 31,204 shares of the medical research company’s stock worth $8,872,000 after purchasing an additional 1,909 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Performance

AMGN opened at $283.61 on Friday. The firm has a market cap of $152.45 billion, a P/E ratio of 36.31, a price-to-earnings-growth ratio of 2.69 and a beta of 0.60. The business’s fifty day moving average is $320.85 and its 200-day moving average is $318.36. Amgen Inc. has a 52-week low of $260.52 and a 52-week high of $346.85. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. During the same period in the prior year, the company posted $4.96 earnings per share. The business’s revenue for the quarter was up 23.2% on a year-over-year basis. Sell-side analysts expect that Amgen Inc. will post 19.51 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 3.17%. The ex-dividend date is Monday, November 18th. Amgen’s payout ratio is 115.24%.

Analysts Set New Price Targets

AMGN has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $305.00 price target (down previously from $310.00) on shares of Amgen in a report on Wednesday, August 7th. William Blair reissued an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. TD Cowen raised their price target on Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a report on Monday, October 21st. Dbs Bank raised shares of Amgen to a “strong-buy” rating in a research report on Monday, September 16th. Finally, Sanford C. Bernstein initiated coverage on shares of Amgen in a research report on Thursday, October 17th. They issued an “outperform” rating and a $380.00 price objective on the stock. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $333.57.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.